Multiple Myeloma Stem Cell Treatment in Delhi, India

Multiple myeloma is a rare form of blood cancer that affects the plasma cells of the immune system. Plasma cells produce immunoglobulins, or antibodies, that help the body defend against infection.

Abnormal plasma cells multiply and mutate, creating a range of medical issues. Multiple myeloma can seriously affect your bones, kidneys, and red and white blood cells, as well as your platelet count. Unfortunately, there is no cure, but treatment options can be used to slow the progression of the disease and manage symptoms.

In people with multiple myeloma, plasma cells crowd out normal blood cells in the bones, which leads to lytic lesions. These cells also release chemicals that cause other cells to erode the bone, resulting in further damage.

As the condition progresses, the plasma cells spread beyond the bone marrow, causing organ damage.

Multiple myeloma is more prevalent in men than in women, and Black individuals are affected at roughly twice the rate of individuals of other races. In addition, individuals aged between 40 and 70 are most likely to be diagnosed with the condition, with the median age of diagnosis ranging from 65 to 74.

Treatment options for multiple myeloma vary depending on the severity of the condition. In cases where the disease is slow-growing, close monitoring alone may be an appropriate initial approach.

However, when treatment becomes necessary, chemotherapy, radiation therapy, and treatments such as bone marrow transplant for multiple myeloma in India may be used to help control the disease.

Stem Cell Care India aims to help patients achieve the best possible results with multiple myeloma bone marrow transplants in Delhi. We are dedicated to providing exceptional care and support to our patients as they work toward improved health and well-being.

Pain in the bones is often the initial symptom that individuals experience with multiple myeloma. Other symptoms can include:

• Weakness and/or tingling sensations in the limbs.
• Bones in the spine may be affected by multiple myeloma, leading to their collapse and compression of the spinal cord.
• Fatigue and feeling weak, which may indicate anemia.
• Feeling nauseous and vomiting, which might indicate hypercalcemia.
• Lack of appetite and increased thirst.
• Unintended weight loss.
• Unexplained fever, which may be a symptom of a bacterial infection.
• Bruising or bleeding more easily than usual, which may be a sign that abnormal plasma cells are preventing the body from producing enough platelets.
• Difficulty concentrating or making decisions.

In people with multiple myeloma, the cancerous plasma cells produce abnormal proteins that can damage the bones, organs, and tissues. The disease can spread to other parts of the body.

With multiple myeloma, cancerous plasma cells divide and grow uncontrollably within the bone marrow, producing abnormal proteins that can lead to damage to bones, organs, and tissues.

Listed below are some main subtypes of multiple myeloma:

• Hyperdiploid: Approximately 45% of multiple myeloma cases involve an abnormal type of myeloma cell with an increased number of chromosomes compared to normal cells. This type tends to be less aggressive.
• Hypodiploid or non-hyperdiploid: Approximately 40% of individuals with myeloma have a more aggressive form of the disease, characterized by fewer chromosomes than normal myeloma cells.

Certain precancerous conditions and related subtypes may also occur, including:

• Light chain myeloma: Myeloma usually involves the production of complete immunoglobulins, but in some cases only an incomplete form of these antibodies, known as light chains, is produced. This occurs in around 20% of myeloma patients and can lead to kidney damage.
• Solitary plasmacytoma: Plasmacytoma is a tumor caused by cancerous plasma cells growing out of control; a solitary plasmacytoma is a single tumor, while multiple myeloma involves multiple tumors.
• Non-secretory myeloma: People with non-secretory myeloma may not produce enough M proteins or light chains for tests to detect. A bone marrow biopsy is often used to diagnose this type.
• Extramedullary plasmacytoma: These are tumors in the body’s soft tissues, often occurring in the throat, sinuses, nose, and larynx. Treatment options include radiation therapy, surgery, or both, and this condition can progress to multiple myeloma in up to 30% of cases.
• IgD myeloma: 1% to 2% of people with myeloma have this rare type, which primarily affects men under 60; signs and symptoms are similar to other types.
• IgE myeloma: IgE myeloma is a rare form of multiple myeloma with symptoms similar to other types, but it tends to be more aggressive and can progress more rapidly to plasma cell leukemia or other extramedullary spread.

Scientists have yet to determine the precise cause of most cases of multiple myeloma. Nevertheless, they have made progress in understanding how changes in DNA can lead to the transformation of plasma cells into cancerous cells. DNA is the molecule that holds the instructions for most of our cells’ activities.

• Some DNA contains genes that control when cells grow and divide. Genes that promote cell growth are called oncogenes.
• Genes that control the rate of cell growth and cause cells to die at the appropriate time are called tumor suppressor genes.

Mutations in DNA that activate oncogenes or deactivate tumor suppressor genes can lead to the development of cancer.

Research has shown that certain oncogenes, such as MYC, show abnormalities in the early stages of plasma cell tumors, while alterations in other oncogenes, such as RAS, are commonly seen in myeloma cells at later stages. Mutations in tumor suppressor genes, such as p53, are associated with the spread of cancer to other parts of the body.

Studies have also found that patients with plasma cell tumors have abnormalities in bone marrow cells, which may contribute to excess plasma cell growth. Certain cells in the bone marrow secrete IL-6, a cytokine that stimulates normal plasma cell growth and may contribute to abnormal growth when regulation is disrupted.

Occasionally, multiple myeloma is identified unexpectedly through a blood test conducted for a different purpose. Alternatively, if your doctor suspects multiple myeloma based on your signs and symptoms, they may order tests to confirm the diagnosis.

Diagnosing multiple myeloma may involve tests and procedures such as:

• Blood tests: A laboratory analysis of your blood can reveal the presence of M proteins produced by myeloma cells. Additionally, beta-2-microglobulin, another protein associated with myeloma cells, may be measured and can provide insight into the aggressiveness of the disease. Blood tests assessing kidney function, blood cell counts, calcium levels, and uric acid levels can also help inform the diagnosis.
• Urine tests: A urine analysis may reveal the presence of M proteins, also known as Bence Jones proteins.
• Tests of your bone marrow: Your doctor may take a sample of bone marrow for laboratory examination by performing a bone marrow aspiration and biopsy, which involves inserting a long needle into a bone. The sample is then tested for myeloma cells, and specialized tests such as FISH (fluorescence in situ hybridization) can be used to detect gene mutations.
• Imaging examination: Imaging tests such as X-ray, MRI, CT, or a PET scan may be recommended to identify bone issues related to multiple myeloma.

At Stem Cell Care India, we believe in a multidisciplinary approach to treating patients with multiple myeloma. Our team of medical experts collaborates to assess each individual’s condition and provide the information needed to make informed decisions about care.

For your unique multiple myeloma diagnosis and condition, we create a personalized treatment plan based on the stage and aggressiveness of the disease, your age, health history, and desired outcome. We aim to treat your condition in the most appropriate manner, using combination therapies to give you the greatest likelihood of a successful outcome.

A multiple myeloma bone marrow transplant can be a powerful tool in combating the condition by replacing unhealthy blood cells with healthy ones.

There are two major types of bone marrow transplant treatments for multiple myeloma:

• Autologous Transplant: This treatment uses the patient’s own bone marrow.
• Allogeneic Transplant: Your healthcare provider uses bone marrow cells from a matched donor for this treatment.

For individuals with multiple myeloma, high-dose cancer treatment is often necessary. However, this intensive treatment can damage the bone marrow, the spongy tissue inside bones responsible for producing blood cells. To counteract this, a myeloma bone marrow transplant can be performed to restore the marrow and support healthy blood production.

By establishing standards for stem cell transplantation for multiple myeloma and applying innovative approaches to treatment, we are working to improve long-term outcomes for patients undergoing blood and bone marrow transplantation.

Our multiple myeloma bone marrow transplant program includes outpatient procedures, enabling patients receiving autologous transplants to return home after treatment. This option is highly regarded by patients for the increased autonomy it provides and has contributed to strong patient satisfaction.

Bone marrow transplantation is a technique used to treat cancer by replacing unhealthy, cancerous cells in a person’s bone marrow with fresh, new blood-forming stem cells. This process offers a chance at improved health for those affected by the disease.

Two different approaches exist for infusing healthy stem cells: allogeneic and autologous. In the allogeneic method, stem cells are taken from a donor, either unrelated or partially mismatched. Autologous transplantation uses stem cells that originate from the patient themselves, collected before chemotherapy. Both approaches suppress the patient’s immune system, making it easier for the transplanted cells to integrate and grow.

After cancerous cells have been eliminated from the patient’s bone marrow, healthy stem cells from a donor are infused into the patient’s bloodstream, much like a blood transfusion. These transplanted cells travel to the patient’s bone marrow and begin forming healthy blood cells.

Finding the right match for a patient in need of donor stem cells can be a lengthy process. With the help of a sibling or an unrelated donor, the odds of a successful transplant increase considerably. Once the donor and patient are matched, the healthy stem cells can be transplanted and will replicate, creating new blood cells and bone marrow that support the patient’s immune system going forward.

The implantation process in a bone marrow transplant is crucial to the success of the procedure. Implantation, also known as engraftment, involves the infusion of healthy donor stem cells into the recipient’s bloodstream, where they travel to the bone marrow and begin producing new blood cells.

The following methods can be used to perform stem cell implantation:

• Intramuscular
• Intra-arterial
• Intravenous administration
• Intrathecal (lumbar puncture)
• Subcutaneous

This process is a critical component of bone marrow transplant and must be carefully managed to ensure the best possible outcome for the patient.

A stem cell transplant can be a powerful option for treating multiple myeloma, replacing unhealthy cells with healthy stem cells that can develop into a range of blood cells. These new cells help restore the body’s normal function.

• Red blood cells, also known as erythrocytes, are responsible for transporting oxygen throughout the body and are essential for its proper functioning.
• White blood cells, also known as immune cells, play a vital role in fighting off infections.
• Platelets are an essential component of the blood, helping it clot and preventing excessive bleeding.

In a multiple myeloma bone marrow transplant, a high dose of chemotherapy is used to destroy cells in the bone marrow, including cancer cells. Healthy stem cells are then transplanted, either from the patient (autologous) or a donor (allogeneic).

For some people with multiple myeloma, a bone marrow transplant may be an effective treatment option. During this procedure, a high dose of chemotherapy is used to destroy cancer cells in the bone marrow.

Afterward, stem cells isolated from the blood are transplanted into the patient. These new stem cells begin to develop into healthy blood cells, and it can take several months for blood counts to return to normal.

Although stem cell transplantation for multiple myeloma can improve overall survival, relapses can occur over time. It is important to discuss with a doctor whether a stem cell transplant is a suitable option, as it can be demanding on the body.

Stem cell therapy for Multiple Myeloma is discussed only after an individual medical evaluation, and safety depends heavily on that case-by-case review rather than on the therapy in general. As with any medical intervention, mild and temporary reactions (such as soreness or fatigue at the injection or infusion site) are possible, and a full risk discussion happens as part of your evaluation. It is not offered to patients in an acute or unstable phase of Multiple Myeloma, and it is never positioned as a substitute for guideline-based care from your treating specialist. For a fuller picture of how safety, accreditation, and quality standards are handled, see our Safety and Guarantees page.

This list is general and educational — it is not a substitute for an individual medical evaluation of your case.

A supportive-care discussion for Multiple Myeloma isn't a single conversation — it follows a defined sequence, so nothing is recommended before your specific case has been reviewed. In broad terms:

1. Record review: Your existing diagnosis, imaging, lab work, and treatment history for Multiple Myeloma are reviewed by the medical team first.
2. Case-by-case medical evaluation: A physician assesses whether any further discussion is medically reasonable for your specific case — many enquiries end here with a clear "not appropriate" answer, which is a valid and expected outcome.
3. Coordination with your specialist: Where a discussion proceeds, it is coordinated so it does not conflict with your ongoing care from your treating specialist.
4. Transparent, written explanation: Any recommendation is explained in plain language, including its investigational status, realistic expectations, and that no outcome is guaranteed.
5. Ongoing standard care continues: At every stage, your prescribed treatment for Multiple Myeloma continues unless your own treating specialist changes it.

Nothing is scheduled or billed during this stage — it is a review and conversation, not a commitment.

At all times, we strive to bring hope and healing to those we serve. We are committed to providing access to groundbreaking treatments, top-of-the-line amenities, and world-renowned care. Our in-house medical team is dedicated to developing innovative and effective treatments that combine international standards with unique products and services. Our aim is to provide patients with the most beneficial care and treatment outcomes for their individual health conditions. We are proud to share that our dedication to hope and healing has enabled us to bring lasting relief to thousands of individuals.

In recent years, bone marrow transplants for multiple myeloma have become an increasingly common treatment option. The procedure has been used to treat a variety of cancers and blood disorders, including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, aplastic anemia, thalassemia, and sickle cell anemia. It has also been used for some solid tumors and other genetic and immune-mediated diseases.

The success of bone marrow transplantation is largely due to advances in technology and technique made over the years.

If you’re curious about the cost of bone marrow transplants in Delhi, the answer may depend on a variety of factors, such as:

• The location of the hospital
• The relationship between the donor and patient
• Type of multiple myeloma bone marrow transplant in Delhi
• The overall condition and age of the patient
• Diagnosis, examinations, and lab tests

The strong success rates of our treatments and the affordability of our bone marrow transplants have made India a well-known destination for international patients seeking cost-effective medical care.

If you’d like to learn more about our multiple myeloma stem cell therapy or bone marrow treatment, our team of knowledgeable professionals is here to help. They can take you through the entire process and offer round-the-clock guidance and support every step of the way. Get in touch today!

Replacing unhealthy cells with healthy ones, a bone marrow transplant offers hope for those living with multiple myeloma. This treatment has the potential to reduce the risk of further bone marrow damage and relapse, ultimately providing a better chance of survival.

India has become a recognized destination for bone marrow treatment, offering cost-effective and successful services. Patients from around the world travel to India for treatment, drawn by its effectiveness and comparatively lower cost relative to other countries.

The likelihood of success for any individual patient can be evaluated through a comprehensive assessment of their medical history, performance status, other medical conditions, family support structure, financial standing, and personal engagement with their own healthcare.

Through this process, a multivariate analysis can be conducted to determine outcome expectations for the patient. A thorough health history, physical examination, and clinical testing are then carried out to confirm the patient’s physiological condition.

A bone marrow transplant is a therapy that offers hope for those suffering from diseased or damaged bone marrow. Healthy stem cells are taken from either the patient’s own body or a donor and transferred into the patient, replacing the faulty cells. This process is used to treat a variety of cancers, including myeloma, as well as other blood and immune system disorders.

With multiple myeloma stem cell therapy or bone marrow transplant, Delhi is a leading destination for a reliable treatment option for myeloma.

At Stem Cell Care India, we understand that a bone marrow transplant is a significant decision. That’s why we provide a variety of advantages for choosing this treatment, including:

• After just a three-day stay in the hospital, patients are able to go back to their daily routines.
• We will be with you every step of the way to make sure your journey to India is as smooth as possible, from planning to post-treatment follow-up care.
• At our facility, our team of dedicated, highly trained professionals ensures that each treatment is both safe and effective.
• Affordability meets world-class quality at SCCI — a bone marrow transplant is available at a fraction of the cost compared to treatment in Western countries, with first-rate care in a state-of-the-art facility.

Stem Cell Care India is dedicated to advancing the healthcare sector with stem cell treatment that is accessible to all. Our strict quality control standards ensure that treatment is reliable and trustworthy. Our quality control guidelines include:

• Prior to being examined, each collection of stem cells is rigorously screened for microbial pathogens.
• We take extra precautions to make sure our stem cells and media are free from Gram bacteria and mycoplasma, thoroughly inspecting them for any signs of contamination.
• To ensure stem cell safety, endotoxin screening is a crucial measure; batches are only approved if endotoxin levels fall below a predetermined threshold.
• Scientists continually examine stem cells to detect any abnormalities or harmful microbes that could create a problem during treatment or cause harm to the patient.
• A Certificate of Analysis accompanies every collection of stem cells, confirming that they have undergone appropriate testing and can be used with confidence.

The success of a bone marrow transplant can be greatly influenced by the genetic similarity between the donor and recipient. Finding a compatible donor can be challenging, especially when donor and recipient are not related.

Advances in medical science have led to increased success in bone marrow transplants over time.

Treatment outcomes and recovery may depend on the following:

• The state of the patient’s overall health
• The type of transplant performed
• The body’s acceptance of the donor’s marrow
• The amount of chemotherapy and/or radiation the patient underwent
• The patient’s ability to fight infection

Issa Ayad visited India for bone marrow treatment

Hi, I am Issa from Abu Dhabi, and I can’t express how grateful I am for the bone marrow treatment I received for multiple myeloma in India. Thanks to this treatment, I am now in remission and able to enjoy life again. The entire process was smooth and painless, and I am so thankful for the medical professionals at Stem Cell Care who made it possible.

Adam Scott from Germany came to us for multiple myeloma treatment

I was diagnosed with multiple myeloma a few years ago, and after trying several treatments with little success, my doctor recommended bone marrow treatment in Delhi, India. I was nervous at first, but the results were incredible. My cancer has not only gone into remission, but my overall health has improved considerably. I would highly recommend a multiple myeloma bone marrow transplant to anyone facing this condition.

Priya Thapa’s success story of effective bone marrow transplant

As someone who has undergone bone marrow treatment for multiple myeloma at Stem Cell Care India, I can confidently say that it was the best decision I made for my health. The procedure was painless, and the recovery was quick. The results were remarkable, and I am now cancer-free. I would encourage anyone facing a similar diagnosis to consider bone marrow treatment as a viable option.

Morcos from the UAE visited India for the treatment of his mother

My mother was diagnosed with multiple myeloma, and we were all worried about her prognosis. However, after undergoing bone marrow treatment at Stem Cell Care India, she has made an incredible recovery. Her cancer is in remission, and her quality of life has vastly improved. We are so grateful for this treatment and the amazing medical team who made it possible.

Every patient in need of medical treatment is given assurance that the cells being used in their care are of the highest quality, quantity, and viability, through a certified laboratory’s rigorous verification process. This provides medical professionals with confidence that the patient is receiving the best and safest care possible.

Ensuring the highest quality of care for a patient is paramount, and the verification process is key in this regard, confirming that the cells used are of the highest caliber and in optimal condition for the best possible outcome.

The team at Stem Cell Care India will remain by your side for the coming eighteen months, checking in with you after one month, two months, and six months. We use this time to refine our processes and make sure our services are always top-notch. You are free to reach out to us anytime you feel the need for extra assistance.

Stem cell therapy is generally discussed as one part of a broader recovery plan rather than a stand-alone treatment. Supportive therapies sometimes used alongside it for multiple myeloma include:

• Psychological support: To help address mood changes, anxiety, or emotional stress that can follow a multiple myeloma.
• Speech therapy: For patients experiencing difficulty speaking, swallowing, or understanding language.
• Physiotherapy: To help rebuild movement, balance, and muscle strength.
• Hyperbaric oxygen therapy: Delivering oxygen at increased pressure, which is being explored as a supportive measure for tissue recovery.
• Acupuncture: Used by some patients as a complementary approach alongside conventional care.
• Rehabilitation therapy: Structured practice of daily tasks to support functional recovery.
• Occupational therapy: Support for relearning tasks such as dressing, eating, and writing.
• Nutrition therapy: Dietary guidance intended to support general recovery.
• Nerve Growth Factor (NGF) treatment: Supports the survival and growth of nerve cells; when discussed alongside stem cell therapy, it is explored for its potential to support nerve repair and overall brain recovery.

Any combination of these should be planned together with the treating medical team rather than pursued independently.

Multiple myeloma affects patients worldwide, and because it can disrupt memory, movement, or cognitive activity, many patients look beyond their home country for treatment options to discuss with a physician. A number of international patients — including from the United States, Europe, the United Kingdom, the UAE, Thailand, and Nepal — have looked into evaluation and care options in India as part of that search. Considerations patients commonly cite when comparing India with other locations include:

• Established medical infrastructure and equipment at accredited facilities
• A large pool of trained physicians and researchers, including many with international training
• Costs that are often lower than in Western countries for comparable services
• Individualized treatment planning tailored to each patient's needs
• Support services such as airport transfers, medical visa assistance, and multilingual staff for international patients
• Access to post-treatment rehabilitation support, including physiotherapy and follow-up consultation
• Positive treatment experiences reported by many patients who have travelled for care, though individual outcomes still vary

These are general considerations reported by patients and are not a guarantee of any particular outcome, cost, or experience.

Autologous and allogeneic stem cell transplantation for multiple myeloma is one of the most extensively studied areas of blood cancer treatment. Some key sources include:

• Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma Patients: A 5-Year Experience from a Single Centre in North India – a study on ASCT outcomes for myeloma in an Indian clinical setting. https://pubmed.ncbi.nlm.nih.gov/37969670/
• Nishimura K.K. et al., "Long-term outcomes after autologous stem cell transplantation for multiple myeloma," Blood Advances, 2020 – a long-term outcomes analysis of ASCT in myeloma patients. https://pubmed.ncbi.nlm.nih.gov/35203257/
• "Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?" – a review discussing how ASCT provides a progression-free survival benefit in eligible myeloma patients. https://pubmed.ncbi.nlm.nih.gov/33777050/
• ClinicalTrials.gov (U.S. National Library of Medicine) – Registry of ongoing and completed clinical trials on stem cell transplantation for multiple myeloma. https://clinicaltrials.gov/search?cond=Multiple%20Myeloma&term=stem%20cell%20transplant
• Indian Council of Medical Research (ICMR) – National Guidelines for Stem Cell Research, which govern the ethical and clinical use of stem cell-based therapies, including bone marrow transplantation, within India.